MycRx unveiled as the new brand identity for MecRx Pty Ltd.
MecRx Pty Ltd has announced a new trading name that reflects the focus of the company on the development of small molecule inhibitors that bind directly to Myc.
The company’s new website mycrxpharma.com will launch in early 2021.
MecRx receives $50,000 Therapeutic Innovation Australia Pipeline Accelerator funding.
MecRx Pty Ltd has been awarded $50,000 of Pipeline Accelerator funding by Therapeutic Innovations Australia to access ADME/PK facilities and expertise at the Centre for Drug Candidate Optimisation (CDCO), Monash University. The TIA Pipeline Accelerator funding will allow MecRx to expand the preclinical testing of its novel small molecule inhibitors of the protein Myc and advance the progression of the research program to develop a Myc inhibitor for clinical testing in cancer patients.
Dr Sangkyu Kim awarded Industry Fellowship.
MecRx’s Biology Programme Manager Dr Sangkyu Kim has been awarded a Bridge and BridgeTech Industry Fellowship Placement through the MTPConnect Researcher Exchange and Development through Industry (REDI) initiative. As part of the Bridge and BridgeTech Industry Fellowships Program, Dr Kim will undertake a placement within a large pharmaceutical industry partner with a funded fellowship which will aim to enhance his commercial skills and experience in the industry.
MecRx awarded $900,000 Biomedical Translation Bridge Award by MTP Connect.
MecRx Pty Ltd has been announced as one of the eight successful applicants for Round One funding from the Biomedical Translation Bridge Program to develop novel, small molecule therapeutics for the treatment of lung cancer.
The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund, providing up to $1 million in matching funding to nurture the translation of new therapies, technologies and medical devices through to the proof-of-concept stage.MORE
The BTB program is operated by MTPConnect, in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.
MecRx awarded a second SIEF Ross Metcalf STEM+ Business Fellowship.
MecRx has been awarded an additional $210,000 of funding from the Science and Industry Endowment Fund (SIEF) for a second STEM+ Research Fellowship. The funding will facilitate an additional early career post-doctoral research fellow to be placed within the existing Medicinal Chemistry team based at CSIRO for a period of two years, working to improve the drug-like qualities of the MecRx lead compounds and contribute to the design and improvement of new synthetic routes and scale up chemistry.
MecRx awarded a second Innovation Connections grant.
MecRx Pty Ltd has been awarded a second Innovation Connections Grant to the value of $50,000 to facilitate placement of two researchers at the Centre for Drug Candidate Optimisation (CDCO), Monash University. These researchers will continue work assessing the physicochemical and biopharmaceutical properties of novel MecRx compounds in order to identify suitable compounds to progress toward development as a clinical candidate.
MecRx secures $4M investment.
A risk-sharing agreement with CSIRO saw Melbourne start-up biotech company MecRx secure a $4 million investment from the Medical Research Commercialisation Fund (MRCF) to advance its breakthrough technology for accelerating drug discovery.